þ | No fee required. |
o | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
(1) | Title of each class of securities to which transaction applies: |
(2) | Aggregate number of securities to which transaction applies: |
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
(4) | Proposed maximum aggregate value of transaction: |
(5) | Total fee paid: |
o | Fee paid previously with preliminary materials |
o | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
(1) | Amount previously paid: |
(2) | Form, Schedule or Registration Statement No.: |
(3) | Filing Party: |
(4) | Date Filed: |
You May Vote Your Proxy When You View The Material On The Internet. You Will Be Asked To Follow The Prompts To Vote Your Shares. | |
c/o Continental Proxy Services - 8th Floor 17 Battery Place, New York NY 10004-1123 | Cumberland Pharmaceuticals 2525 West End Ave, Suite 950, Nashville, TN 37203 |
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS to be held on Tuesday, April 25, 2017 |
*Shareholders are cordially invited to attend the Annual Meeting and vote in person. At the meeting, you will need to request a ballot to vote your shares. |
(1) | To consider and act upon a proposal to elect to the Company’s Board of Directors, Joey A. Jacobs, Caroline R. Young, Kenneth J. Krogulski, and Jonathan I. Griggs nominated by the Board of Directors; |
(2) | To ratify a proposal to consider the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the 2017 fiscal year; |
(3) | To provide advisory approval of all of the compensation of the Company's named executive officers as disclosed pursuant to Item 402 of Regulation S-K including the Compensation Discussion and Analysis compensation tables and narrative discussion; |
(4) | To provide advisory approval of the frequency of the advisory vote on all of the compensation of the Company's named executives (The Board recommends "Every Three Years"); |
(5) | To approve extension of the Amended and Restated 2007 Long-Term and Directors' Incentive Compensation Plans through April 18, 2020. |
Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned the proxy card. | Vote Your Proxy on the Internet: Go to http://www.cstproxyvote.com Have your notice available when you access the above website. Follow the prompts to vote your shares. | |
COMPANY ID: | ||
PROXY NUMBER: | ||
The Proxy Materials are available for review at: http://www.cstproxy.com/cumberlandpharma/2017 | ACCOUNT NUMBER: |
• | Annual Report for the year ended December 31, 2016. |
• | 2017 Proxy Statement. |
• | Proxy Card. |
• | Any amendments to the foregoing materials. |
ACCESSING YOUR PROXY MATERIALS ONLINE Have this notice available when you request a paper copy of the proxy materials or to vote your proxy electronically. You must reference your company ID., proxy number, and account number. |
REQUESTING A PAPER COPY OF THE PROXY MATERIALS By telephone please call 1-888-221-0690, or By logging on to http://www.cstproxy.com/cumberlandpharma/2017 or By email at: proxy@continentalstock.com Please include the company name and your account number in the subject line. |